Prognostic significance of circulating tumour biomarkers in patients treated with curative-intent radiotherapy for NSCLC [ 2016 - ]

Research Grant

Researchers: Prof Michael MacManus (Principal investigator) ,  A/Pr Olga Martin ,  Dr Maximilian Diehn ,  Prof David Ball ,  Prof Erik Thompson

Brief description More than 50% of cancer patients in Australia receive radiotherapy but many later die from distant metastases. This study of circulating biomarkers (tumour cells and DNA in the bloodstream) builds on evidence from research at Peter Mac showing that some lung cancers might spread during treatment with radiotherapy that would otherwise be curative. This study will help identify cancer patients at high risk of secondary cancers and could allow us to modify treatments to prevent them.

Funding Amount $877,098.00

Funding Scheme Project Grants

Notes Standard Project Grant